Caris Life Sciences, Inc. (CAI) Stock Forecast & Price Target

Compare

129 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CAI Analyst Ratings

Strong Buy

7 Buy

1 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Caris

Life Sciences, Inc.

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CAI Stock 12 Month Forecast

Average Price Target

$34.71

▲(77.73% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Caris Life Sciences, Inc. in the last 3 months. The average price target is $34.71 with a high forecast of $40.00 and a low forecast of $26.00. The average price target represents a 77.73% change from the last price of $19.53.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","41":"$41","26.75":"$26.8","31.5":"$31.5","36.25":"$36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,26.75,31.5,36.25,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Jul<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.32,24.603076923076923,25.886153846153846,27.16923076923077,28.45230769230769,29.735384615384614,31.018461538461537,32.30153846153846,33.58461538461538,34.86769230769231,36.15076923076923,37.433846153846154,38.71692307692308,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.32,24.196153846153848,25.072307692307692,25.94846153846154,26.824615384615385,27.700769230769232,28.576923076923077,29.453076923076924,30.32923076923077,31.205384615384617,32.081538461538464,32.95769230769231,33.83384615384615,{"y":34.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.32,23.526153846153846,23.732307692307693,23.93846153846154,24.144615384615385,24.35076923076923,24.556923076923077,24.763076923076923,24.96923076923077,25.175384615384615,25.38153846153846,25.587692307692308,25.793846153846154,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.25,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27.25,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.04,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.33,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.98,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.32,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$40.00

Average Price Target$34.71

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Catherine Ramsey Schulte

Robert W. Baird

$26

Buy

33.13%

Upside

Initiated

02/17/26

Caris Life Sciences initiated with an Outperform at BairdCaris Life Sciences initiated with an Outperform at Baird

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$36

Buy

84.33%

Upside

Reiterated

02/04/26

Guggenheim Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)

Kyle Mikson CFA

Canaccord Genuity

$30

Hold

53.61%

Upside

Reiterated

01/26/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Neurocrine (NASDAQ: NBIX)

Daniel Brennan

TD Cowen

$38

Buy

94.57%

Upside

Reiterated

01/07/26

Patrick B Donnelly

Citi

$42→

Buy

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Ardent Health Partners, Inc. (NYSE: ARDT)

Vijay Kumar

Evercore ISI

$40→$38

Buy

94.57%

Upside

Reiterated

01/05/26

Caris Life Sciences price target lowered to $38 from $40 at Evercore ISICaris Life Sciences price target lowered to $38 from $40 at Evercore ISI

Michael Ryskin

Bank of America Securities

$39→$35

Buy

79.21%

Upside

Reiterated

12/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Caris Life Sciences, Inc. (NASDAQ: CAI) and Doximity (NYSE: DOCS)

Casey Woodring

J.P. Morgan

$40

Buy

104.81%

Upside

Reiterated

12/15/25

J.P. Morgan Reaffirms Their Buy Rating on Caris Life Sciences, Inc. (CAI)

Mark Massaro

BTIG

$45

Buy

130.41%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Accuray (NASDAQ: ARAY), Evolus (NASDAQ: EOLS) and Caris Life Sciences, Inc. (NASDAQ: CAI)

Doug Schenkel

Wolfe Research

$32

Buy

63.85%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Catherine Ramsey Schulte

Robert W. Baird

$26

Buy

33.13%

Upside

Initiated

02/17/26

Caris Life Sciences initiated with an Outperform at BairdCaris Life Sciences initiated with an Outperform at Baird

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

$36

Buy

84.33%

Upside

Reiterated

02/04/26

Guggenheim Sticks to Its Buy Rating for Caris Life Sciences, Inc. (CAI)

Kyle Mikson CFA

Canaccord Genuity

$30

Hold

53.61%

Upside

Reiterated

01/26/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI), Madrigal Pharmaceuticals (NASDAQ: MDGL) and Neurocrine (NASDAQ: NBIX)

Daniel Brennan

TD Cowen

$38

Buy

94.57%

Upside

Reiterated

01/07/26

Patrick B Donnelly

Citi

$42→

Buy

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Ardent Health Partners, Inc. (NYSE: ARDT)

Vijay Kumar

Evercore ISI

$40→$38

Buy

94.57%

Upside

Reiterated

01/05/26

Caris Life Sciences price target lowered to $38 from $40 at Evercore ISICaris Life Sciences price target lowered to $38 from $40 at Evercore ISI

Michael Ryskin

Bank of America Securities

$39→$35

Buy

79.21%

Upside

Reiterated

12/15/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (NASDAQ: CYTK), Caris Life Sciences, Inc. (NASDAQ: CAI) and Doximity (NYSE: DOCS)

Casey Woodring

J.P. Morgan

$40

Buy

104.81%

Upside

Reiterated

12/15/25

J.P. Morgan Reaffirms Their Buy Rating on Caris Life Sciences, Inc. (CAI)

Mark Massaro

BTIG

$45

Buy

130.41%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: Accuray (NASDAQ: ARAY), Evolus (NASDAQ: EOLS) and Caris Life Sciences, Inc. (NASDAQ: CAI)

Doug Schenkel

Wolfe Research

$32

Buy

63.85%

Upside

Initiated

07/14/25

Caris Life Sciences initiated with an Outperform at Wolfe ResearchCaris Life Sciences initiated with an Outperform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Caris Life Sciences, Inc.

3 Months

xxx

Success Rate

1/3 ratings generated profit

Average Return

-8.53%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -8.53% per trade.

1 Year

Mark MassaroBTIG

Success Rate

0/3 ratings generated profit

Average Return

-20.00%

reiterated a buy rating 4 months ago

Copying Mark Massaro's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -20.00% per trade.

2 Years

xxx

Success Rate

0/3 ratings generated profit

Average Return

-20.00%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -20.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CAI Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CAI has received 8 Buy Ratings, 19 Hold Ratings, and 0 Sell Ratings. CAI average Analyst price target in the past 3 months is 34.71.

Each month's total comprises the sum of three months' worth of ratings.

CAI Financial Forecast

CAI Earnings Forecast

Next quarter’s earnings estimate for CAI is $0.03 with a range of -$0.01 to $0.10. The previous quarter’s EPS was $0.08. CAI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year CAI has Performed in-line its overall industry.

CAI Sales Forecast

Next quarter’s sales forecast for CAI is $240.39M with a range of $204.00M to $281.00M. The previous quarter’s sales results were $216.83M. CAI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year CAI has Performed in-line its overall industry.

CAI Stock Forecast FAQ

What is CAI’s average 12-month price target, according to analysts?

Based on analyst ratings, Caris Life Sciences, Inc.’s 12-month average price target is 34.71.

What is CAI’s upside potential, based on the analysts’ average price target?

Caris Life Sciences, Inc. has 77.73% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CAI a Buy, Sell or Hold?

Caris Life Sciences, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 1 hold ratings and 0 sell ratings.

What is Caris Life Sciences, Inc.’s price target?

The average price target for Caris Life Sciences, Inc. is 34.71. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $26.00. The average price target represents 77.73% Increase from the current price of $19.53.

What do analysts say about Caris Life Sciences, Inc.?

Caris Life Sciences, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of CAI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Caris Life Sciences, Inc. (CAI) Stock Forecast & Price Target

CAI Analyst Ratings

CAI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Caris Life Sciences, Inc.

CAI Analyst Recommendation Trends

CAI Financial Forecast

CAI Earnings Forecast

CAI Sales Forecast

CAI Stock Forecast FAQ

Detailed List of Analyst Forecasts